Results 81 to 90 of about 61,637 (294)
A common issue in clinical drug development involves drug–drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population.
Alice S. Tang+6 more
wiley +1 more source
The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients
The aim of the present study was to investigate the distribution of CYP2C8 variants *3 and *5, as well as their effect on carbamazepine pharmacokinetic properties, in 40 epileptic pediatric patients on carbamazepine treatment.
Milovanovic DD+7 more
doaj +1 more source
Background: Trigeminal neuralgia (TN) is characterized by recurrent attacks of lancinating pain in the trigeminal nerve distribution. Various medicinal and surgical procedures have been utilized for the treatment of TN. Over the time, several drugs other
Nidhi Puri+6 more
doaj +1 more source
Uptake of carbamazepine by rhizomes and endophytic bacteria of Phragmites australis
Carbamazepine is an antiepileptic and mood-stabilizing drug which is used widely in Europe and North America. In the environment, it is found as a persistent and recalcitrant contaminant, being one of the most prominent hazardous pharmaceuticals and ...
A. Sauvêtre, P. Schröder
semanticscholar +1 more source
Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions.
James M. Stevenson+4 more
wiley +1 more source
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith+18 more
wiley +1 more source
Simultaneous qualitative and quantitative analysis of 62 drugs and seven active metabolites in human blood plasma by automated liquid chromatography linear ion trap mass spectrometry. ABSTRACT Rapid and comprehensive qualitative and quantitative analytical procedures are crucial in 24/7 emergency toxicology (ET) to support diagnosis and treatment of ...
Selina Hemmer+4 more
wiley +1 more source
Translocation of pharmaceuticals from wastewater into beehives
There has been a substantial research focus on the presence of pesticides in flowers and the subsequent exposure to honeybees. Here we demonstrate for the first time that honeybees can also be exposed to pharmaceuticals, commonly present in wastewater ...
Laura J. Carter+3 more
doaj
Reflex “toothbrushing” epilepsy: Seizure freedom after focal ablation assisted by ictal fMRI
Abstract A 22‐year‐old female presented with drug‐resistant focal motor seizures with onset at age 14. This manifested as daily episodes of right facial dystonia triggered by toothbrushing, but also by eating, talking, and strenuous exercise. On ictal scalp EEG, there was low‐voltage fast activity over the left pericentral area.
Michael Ginevra+5 more
wiley +1 more source
Abstract Background Alternating Hemiplegia of Childhood (AHC) is a severe channelopathy that manifests before 18 months of age, primarily caused by pathogenic variants in the ATP1A3 gene. It is characterized by recurrent and disabling episodes of plegia, dystonia, dysautonomia, along with chronic neurological features and cardiac arrhythmias. About 50%
Ramona Cordani+8 more
wiley +1 more source